Late last week, AstraZeneca said that it would acquire Alexion Pharmaceuticals ALXN - a company that is best known for its Soliris and Ultomiris drugs which are used to treat rare blood disorders - in ...

We know that hedge funds generate strong, risk-adjusted returns over the long run, therefore imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors ...

Is Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) a good place to invest some of your money right now? We can gain invaluable insight to help us answer that question by studying the investment trends of ...

Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn’t want to find stocks that are either flying under the radar and are ...

Image source: TBIT via pixabay. Alexion Pharmaceuticals' stock is off to a rough start for the year. The company's shares have traded right in lockstep with the biotech stock in general -- as measured ...

Shares in British drugmaker AstraZeneca fell as much as 9% in London trading as markets reacted to news that the company had agreed to buy U.S. Alexion Pharmaceuticals for $39 billion over the weekend ...

Stockholders of Alexion Pharmaceuticals Inc. approved a two-for-one split of the Cheshire drug maker’s stock. The clear way stockholders voting at Alexion’s annual meeting Thursday in New Haven ...

Bridget Leslie, a scientist for Alexion Pharmaceuticals Inc. in Cheshire, monitors a bioreactor in which a key drug ingredient is cultured. HBJ FILE PHOTO Cheshire orphan drug maker Alexion ...

Alexion Pharmaceuticals soared 35% in pre-market trading after the announcement of its $39 billion acquisition by AstraZeneca. The deal has clear gains for both sides, but AstraZeneca's shares slid 6% ...